Full metadata record

DC Field Value Language
dc.contributor.authorLee, D.-H.-
dc.contributor.authorChoi, S.-
dc.contributor.authorPark, Y.-
dc.contributor.authorJin, H.-S.-
dc.date.accessioned2024-01-19T13:33:31Z-
dc.date.available2024-01-19T13:33:31Z-
dc.date.created2022-01-10-
dc.date.issued2021-10-
dc.identifier.issn1424-8247-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/116307-
dc.description.abstractThe mucin (MUC) family is a group of highly glycosylated macromolecules that are abundantly expressed in mammalian epithelial cells. MUC proteins contribute to the formation of the mucus barrier and thus have protective functions against infection. Interestingly, some MUC proteins are aberrantly expressed in cancer cells and are involved in cancer development and progression, including cell growth, proliferation, the inhibition of apoptosis, chemoresistance, metabolic reprogramming, and immune evasion. With their unique biological and structural features, MUC proteins have been considered promising therapeutic targets and also biomarkers for human cancer. In this review, we discuss the biological roles of the transmembrane mucins MUC1 and MUC16 in the context of hallmarks of cancer and current efforts to develop MUC1-and MUC16-targeted therapies. ? 2021 by the authors. Licensee MDPI, Basel, Switzerland.-
dc.languageEnglish-
dc.publisherMDPI-
dc.titleMucin1 and mucin16: Therapeutic targets for cancer therapy-
dc.typeArticle-
dc.identifier.doi10.3390/ph14101053-
dc.description.journalClass1-
dc.identifier.bibliographicCitationPharmaceuticals, v.14, no.10-
dc.citation.titlePharmaceuticals-
dc.citation.volume14-
dc.citation.number10-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000716390800001-
dc.identifier.scopusid2-s2.0-85117912459-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeReview-
dc.subject.keywordPlusEPITHELIAL OVARIAN-CANCER-
dc.subject.keywordPlusGROWTH-FACTOR RECEPTOR-
dc.subject.keywordPlusCELL LUNG-CANCER-
dc.subject.keywordPlusCARCINOMA-ASSOCIATED ANTIGEN-
dc.subject.keywordPlusMUC1 ONCOPROTEIN-
dc.subject.keywordPlusMONOCLONAL-ANTIBODY-
dc.subject.keywordPlusTUMOR-MARKER-
dc.subject.keywordPlusCA 125-
dc.subject.keywordPlusIMMUNOLOGICAL RESPONSE-
dc.subject.keywordPlusMAINTENANCE THERAPY-
dc.subject.keywordAuthorADC (antibody-drug conjugate)-
dc.subject.keywordAuthorCancer vaccine-
dc.subject.keywordAuthorCAR (chimeric antigen recep-tor)-
dc.subject.keywordAuthorImmunotherapy-
dc.subject.keywordAuthorMUC1-
dc.subject.keywordAuthorMUC16-
dc.subject.keywordAuthorMucin-
Appears in Collections:
KIST Article > 2021
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE